Type 1 diabetes (T1D) is a chronic autoimmune disease that in 2022 affected approximately 8.75 million individuals worldwide. T1D is characterized by the loss of pancreatic β-cells responsible for producing insulin, a fundamental hormone that regulates blood glucose levels. Patients with T1D require lifelong insulin replacement through multiple daily insulin injections or insulin pump therapy. However, these therapies don’t fully restore glycemic control and don’t prevent T1D long-term complications such as neuropathy, retinopathy, kidney disease, stroke, macrovascular problems and foot damage. Islet transplantation is a promising alternative to restore the insulin production in a more physiological way, but it still faces significant challenges including the lack of donor availability and requirement of lifelong immunosuppression.